Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers

Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers

Triple-negative breast cancers (TNBCs) are frequently recurrent due to the development of drug resistance post chemotherapy. Both the existing literature and our study found that surface receptor CD47 (cluster of differentiation 47) was upregulated in chemotherapy-treated TNBC cells. The goal of thi...

Full description

Bibliographic Details
Main Authors: Yingnan Si, Ya Zhang, Jia-Shiung Guan, Hanh Giai Ngo, Angela Totoro, Ajeet Pal Singh, Kai Chen, Yuanxin Xu, Eddy S. Yang, Lufang Zhou, Runhua Liu, Xiaoguang (Margaret) Liu
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Vaccines
Subjects:
triple-negative breast cancers
targeted therapy
CD47 receptor
monoclonal antibody
antibody–drug conjugate
Online Access:https://www.mdpi.com/2076-393X/9/8/882

Internet

https://www.mdpi.com/2076-393X/9/8/882

Similar Items